A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

Study Purpose

This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC).

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - For the stage 1: 1.
Male or female subjects aged 18-75 years (inclusive). 2. Female patients of childbearing potential and male patients who have not received vasectomy should use at least one of effective methods of contraception during the whole study and 4 weeks after the last dose of investigational products after signing the informed consent form. The acceptable methods of contraception in this study. 3. The subject has a diagnosis of UC established at least 3 months prior to screening by clinical and endoscopic evidence corroborated by a histopathology report. Subjects are confirmed to have moderate to severe active UC within 14 days prior to the first dose of the investigational product, which is based on a complete Mayo score of 6-12, and an endoscopic subscore of ≥ 2. Endoscopy must be performed during the screening period (day -14 to day -3, allowing centralized reading and evaluation before the first dose at week 0). 4. The subject has evidence of UC extending to the rectum with ≥15 cm involvement on endoscopy. 5. Subjects must be UC patients who are receiving treatment. They can be enrolled if they meet any items below. 1. Prior to the randomization visit, subjects have received oral 5-ASA (e.g., mesalazine, sulfasalazine, olsalazine, balsalazide) for at least 4 weeks with the dose stable for at least 2 weeks. 2. Prior to the randomization visit, subjects have received oral or IV corticosteroids e.g. prednisone (daily doses ≤ 30 mg), budesonide (daily doses ≤ 9 mg), methylprednisolone (daily doses ≤ 24 mg), or equivalent dose of corticosteroids for at least 4 weeks, with the dose stable for at least 2 weeks. 6. If oral 5-ASA or corticosteroid for treatment of UC have been recently discontinued, they must have been stopped for at least 2 weeks prior to the screening endoscopy examination which is used for Mayo score assessment. 7. If subjects use non-prohibited concomitant medications, a stable dosing regimen must be used, that is, within 7 days prior to first dose of investigational product or within 5 half lives of the drug (whichever is longer), there's no new concomitant medications started or changes in the dose of existing non-prohibited concomitant medications. 8. The subject who has extensive colitis or pancolitis of >8 years duration or limited colitis of >12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months prior to initial screening visit (can be performed during Screening if not performed in previous 12 months). 9. Subjects must have documentation of positive herpes zoster virus (VZV) IgG antibody status or complete VZV vaccination at least 30 days prior to randomization. For subjects' entry into the study stage 2 from the stage 1: 1. Subjects must be those with UC who participate in the study of CBP-307CN002 and have completed 12 weeks of treatment with CBP-307 or placebo in the stage 1 and have completed all the assessments (including colonoscopy) at study visit of week 12 in study stage 1. 2. Female subjects of childbearing potential and male subjects who have not received vasectomy should use at least one of the effective methods of contraception during the whole study and 4 weeks after the last dose of investigational products after signing the informed consent form. The acceptable methods of contraception in this study.

Exclusion Criteria:

  • - UC-related

    exclusion criteria:

    1.
At the screening visit, subjects have evidence of toxic megacolon. 2. The subject has had, subtotal or total colectomy. 3. The subject has an existing ileostomy, colostomy (a history of ileostomy or colostomy that has been reversed may be acceptable), or known symptomatic stenosis of the intestine. 4. Investigator judges the subject currently requires or is anticipated to require surgical intervention for UC during the study. 5. The subject has a history or evidence of adenomatous colonic polyps that have not been removed. 6. Subjects were previously exposure to the following treatments:
  • - Lymphocyte-depleting therapies (e.g., alemtuzumab, anti-CD4 antibody, cladribine, rituximab, ocrelizumab, cyclophosphamide, mitoxantrone, total body irradiation, bone marrow transplantation and daclizumab).
  • - Previous treatment with D-penicillamine, leflunomide.
7. Within 60 days prior to the screening visit, the subject has received any of the following for the treatment of UC: 1. Intravenous immunoglobulin; 2. Therapeutic plasma exchange (TPE). 8. Within 30 days prior to randomization visit, the subject has received any of the following for the treatment of UC: 1. Immunosuppressants (such as cyclosporine, tacrolimus, sirolimus or mycophenolate mofetil), thalidomide or traditional Chinese medicine; 2. Approved non-biologic agents or traditional Chinese medicine treatment. 9. Patients who plan to concurrently use an immunosuppressant (such as azathioprine, 6 mercaptopurine or methotrexate) after randomization. Patients treated with azathioprine, 6-mercaptopurine or methotrexate at screening are required to discontinue it prior to the first dose of the study drug. 10. The subject has received any investigational biologic or non-biologic agent, or approved biologic agent or biosimilars within 60 days or 5 half-lives prior to screening (whichever is longer). Exclusion criteria for general conditions: 11. History of uveitis or macular oedema. 12. Clinically relevant cardiovascular conditions, including history or presence of any one of below: 1. Ischemic heart disease or myocardial infarction; History of angina pectoris caused by coronary artery spasm, or raynaud's phenomenon (Raynauds); 2. Congestive heart failure (NYHA class III-IV), cardiac arrest; 3. Stroke, transient ischemic attack; 4. History of recurrent syncope or positive result of vasovagal syncope tilt test; 5. Symptomatic bradycardia, sick sinus syndrome, sinoatrial block, second degree atrioventricular block (e.g., Mobitz type 2 atrioventricular block) or third degree atrioventricular block; 6. Congenital long QT syndrome (LQTS), or prolonged QT interval corrected using Fridericia's fomula (QTcF) in screening ECG (QTcF >450 ms in men, QTcF > 470 ms in women); 7. Subjects at additional risk for QT prolongation due to hypokalemia or hypomagnesemia; or subjects who are on concurrent therapy with QT prolongation drugs (e.g., citalopram, chlorpromazine, haloperidol, methadone, and erythromycin) which result in risk for torsades de pointes; 8. Under treatment or expected to taking treatment during the study with medications with a known impact on the cardiac conduction system (e.g., beta blockers, calcium channel blockers, Class Ia or Class III anti-arrhythmic drugs. (amiodarone, bromobenzylamine, sotalol, ibutilide, azimilide, dofetilide); 9. Hypertension (except well-controlled hypertension after pharmacotherapy); systolic blood pressure < 95 mm Hg or >140 mm Hg and diastolic blood pressure ≤ 50 mm Hg or ≥ 95 mm Hg at the screening visit; 10. Resting heart rate < 55 times/min or ventricular rate < 55 times/min in 12-lead ECG at screening visit; 11. Investigator deems that the 12-lead ECG at screening visit is clinically significant abnormal, such as, myocardial ischemia, any significant cardiac conduction abnormalities (such as the left bundle branch block), that would put the subject at risk or interfere with the study results; 12. Any other significant heart disease that the investigator judges would put the subject at risk or interfere with the study results. 13. Subjects have a family history of premature coronary heart disease. 13. History of type 1 diabetes, uncontrolled type 2 diabetes (HbA1c > 7%) judged by investigator, patients with diabetes accompanied with significant complications, e.g., retinopathy or kidney disease. 14. Pulmonary function test (including examinations of lung ventilation function and pulmonary gas exchange) at the screening visit shows one of the following abnormalities: forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC) < 70% of normal expected value. 15. During screening period, any of the following laboratory abnormalities: 1. HGB < 8 g/dL; 2. WBC count < 3.5 × 10E9/L; 3. Neutrophils count < 1.5 × 10E9/L; 4. Lymphocyte count < 0.8 × 10E9/L; 5. Platelet count < 100 × 10E9/L or >1200 × 10E9/L; 6. Serum creatinine > 124 μmol/L for female or > 141 μmol/L for male; 16. Abnormal liver function test druring the screening period, such as abonormalities in alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (γ-GT), alkaline phosphatase (ALK) or serum total bilirubin, which suggests liver diseases or liver function impairment. 17. If female, the subject is intending to become pregnant before, during, or within 4 weeks after participating in the study or intending to donate ova during such period. 18. If male, the subject intends to donate sperm during the study or for 4 weeks thereafter. Exclusion criteria for infectious diseases: 19. The subject has evidence of known active infection during the screening period. 20. The subject has evidence of treatment for Clostridioides difficile (C. difficile) infection or other intestinal pathogen with 28 days prior to first dose of study drug. 21. Active or latent tuberculosis (TB) evidenced. 22. Chronic hepatitis B virus (HBV) infection* or chronic hepatitis C virus (HCV) infection**. 23. The subject has any identified congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, human immunodeficiency virus [HIV] infection, organ transplantation). 24. The subject has received any live vaccine within 30 days prior to screening, or subjects are scheduled for immunization with any live vaccine during the study or within 1 month after the last dose of the investigational product. 25. Positive syphilis antibody at screening. For subjects' entry into the study stage 2 from the stage 1: 1. Subjects currently have evidence of active or untreated latent tuberculosis. 2. Subjects currently have active or chronic recurrent infections, and in the opinion of the investigator subjects are not eligible to participate in the stage 2 of the study. 3. History of uveitis or macular oedema. 4. Subjects had received any of the following treatments after administration of the first dose in the stage 1 of the study:
  • - Biological product; - Prednisone>30 mg/day, budesonide>9 mg/day, methylprednisolone>24 mg/day or equivalent dose of steroid treatment; - Immunosuppressant (such as azathioprine and 6-mercaptopurine or methotrexate).
5. Investigator deems that the 12-lead ECG results at the study visit of week 12 during study stage 1 is clinically significant abnormal, such as myocardial ischemia, any significant cardiac conduction abnormalities (such as the left bundle branch block), any abnormality that would put the subject at risk or interfere with the study results. 6. Pulmonary function test (including examinations of lung ventilation function and pulmonary gas exchange) of subjects at the study visit of week 12 during the study stage 1 shows 1 of the following abnormalities: forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC) < 50% of normal predicted value. 7. Subjects' laboratory measurements at week 12 visit during the study stage 1 meet any of the following criteria:
  • - AST or ALT> 3 ULN; - Absolute lymphocyte count < 0.2×10E9/L; - Serum creatinine > 124 μmol/L (in females) or > 141 μmol/L (in males) 8.
Any other reason that in the opinion of the investigator may interfere with subject compliance or evaluation of the results of the study

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04700449
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Suzhou Connect Biopharmaceuticals, Ltd.
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Suzhou Connect
Principal Investigator Affiliation Suzhou Connect Biopharmaceuticals, Ltd.
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries China, Ukraine, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Moderate to Severe Ulcerative Colitis
Additional Details

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC). CBP-307 capsules are administered orally. This study includes stage 1 and stage 2. After screening, subjects will enter the randomized, double-blind, placebo-controlled induction therapy for 12 weeks, i.e., the study stage 1. All subjects who complete 12 weeks of induction therapy (with CBP-307 or placebo) in the study stage 1 and complete all examinations (including colonoscopy) at the week 12 visit can choose to enter the study stage 2 of a total of 40 weeks, including 36 weeks of continuous administration and 4 weeks of safety follow-up after the last dose.

Arms & Interventions

Arms

Experimental: CBP-307 capsules Dose 1

CBP-307 capsules Dose 1 oral administration.

Experimental: CBP-307 capsules Dose 2

CBP-307 capsules Dose 2 oral administration.

Placebo Comparator: Placebo capsules

Placebo capsules oral administration.

Interventions

Drug: - CBP-307

CBP-307 capsules oral administration

Drug: - Placebo

Placebo capsules oral administration

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Connect Investigative Site 2311, Hialeah, Florida

Status

Not yet recruiting

Address

Connect Investigative Site 2311

Hialeah, Florida, 33016

Connect Investigative Site 2308, Miami, Florida

Status

Not yet recruiting

Address

Connect Investigative Site 2308

Miami, Florida, 33032

Connect Investigative Site 2302, Orlando, Florida

Status

Not yet recruiting

Address

Connect Investigative Site 2302

Orlando, Florida, 32803

Connect Investigative Site 2304, Orlando, Florida

Status

Not yet recruiting

Address

Connect Investigative Site 2304

Orlando, Florida, 32810

Connect Investigative Site 2306, Orlando, Florida

Status

Not yet recruiting

Address

Connect Investigative Site 2306

Orlando, Florida, 32819

Connect Investigative Site 2307, Atlanta, Georgia

Status

Not yet recruiting

Address

Connect Investigative Site 2307

Atlanta, Georgia, 30309

Connect Investigative Site 2301, Chesterfield, Missouri

Status

Not yet recruiting

Address

Connect Investigative Site 2301

Chesterfield, Missouri, 63005

Connect Investigative Site 2310, Oklahoma City, Oklahoma

Status

Not yet recruiting

Address

Connect Investigative Site 2310

Oklahoma City, Oklahoma, 73122

Connect Investigative Site 2309, Cypress, Texas

Status

Not yet recruiting

Address

Connect Investigative Site 2309

Cypress, Texas, 77429

International Sites

Connect Investigative Site 2018, Hefei, Anhui, China

Status

Recruiting

Address

Connect Investigative Site 2018

Hefei, Anhui, 230001

Connect Investigative Site 2004, Hefei, Anhui, China

Status

Recruiting

Address

Connect Investigative Site 2004

Hefei, Anhui, 230022

Connect Investigative Site 2008, Beijing, Beijing, China

Status

Recruiting

Address

Connect Investigative Site 2008

Beijing, Beijing, 100050

Connect Investigative Site 2001, Beijing, Beijing, China

Status

Recruiting

Address

Connect Investigative Site 2001

Beijing, Beijing, 100730

Connect Investigative Site 2015, Jilin, Changchun, China

Status

Recruiting

Address

Connect Investigative Site 2015

Jilin, Changchun, 130021

Connect Investigative Site 2006, Fuzhou, Fujian, China

Status

Recruiting

Address

Connect Investigative Site 2006

Fuzhou, Fujian, 350001

Connect Investigative Site 2012, Xiamen, Fujian, China

Status

Recruiting

Address

Connect Investigative Site 2012

Xiamen, Fujian, 361004

Connect Investigative Site 2003, Guangzhou, Guangdong, China

Status

Recruiting

Address

Connect Investigative Site 2003

Guangzhou, Guangdong, 510120

Connect Investigative Site 2009, Guangzhou, Guangdong, China

Status

Recruiting

Address

Connect Investigative Site 2009

Guangzhou, Guangdong, 510655

Connect Investigative Site 2017, Shenzhen, Guangdong, China

Status

Recruiting

Address

Connect Investigative Site 2017

Shenzhen, Guangdong, 518035

Connect Investigative Site 2021, Shenzhen, Guangdong, China

Status

Recruiting

Address

Connect Investigative Site 2021

Shenzhen, Guangdong, 518053

Connect Investigative Site 2030, Nanning, Guangxi, China

Status

Recruiting

Address

Connect Investigative Site 2030

Nanning, Guangxi, 168600

Connect Investigative Site 2034, Haikou, Hainan, China

Status

Recruiting

Address

Connect Investigative Site 2034

Haikou, Hainan, 570311

Connect Investigative Site 2026, Shijiazhuang, Hebei, China

Status

Recruiting

Address

Connect Investigative Site 2026

Shijiazhuang, Hebei, 050000

Connect Investigative Site 2041, Shijiazhuang, Hebei, China

Status

Recruiting

Address

Connect Investigative Site 2041

Shijiazhuang, Hebei, 050011

Connect Investigative Site 2022, Zhengzhou, Henan, China

Status

Recruiting

Address

Connect Investigative Site 2022

Zhengzhou, Henan, 450052

Connect Investigative Site 2016, Wuhan, Hubei, China

Status

Recruiting

Address

Connect Investigative Site 2016

Wuhan, Hubei, 430022

Connect Investigative Site 2005, Wuhan, Hubei, China

Status

Recruiting

Address

Connect Investigative Site 2005

Wuhan, Hubei, 430030

Connect Investigative Site 2027, Nanjing, Jiangsu, China

Status

Recruiting

Address

Connect Investigative Site 2027

Nanjing, Jiangsu, 210002

Connect Investigative Site 2031, Nanjing, Jiangsu, China

Status

Recruiting

Address

Connect Investigative Site 2031

Nanjing, Jiangsu, 210006

Connect Investigative Site 2023, Nanjing, Jiangsu, China

Status

Recruiting

Address

Connect Investigative Site 2023

Nanjing, Jiangsu, 210036

Connect Investigative Site 2033, Suzhou, Jiangsu, China

Status

Recruiting

Address

Connect Investigative Site 2033

Suzhou, Jiangsu, 215004

Connect Investigative Site 2025, Dalian, Liaoning, China

Status

Recruiting

Address

Connect Investigative Site 2025

Dalian, Liaoning, 116027

Connect Investigative Site 2028, Jinan, Shandong, China

Status

Recruiting

Address

Connect Investigative Site 2028

Jinan, Shandong, 250012

Connect Investigative Site 2024, Qingdao, Shandong, China

Status

Recruiting

Address

Connect Investigative Site 2024

Qingdao, Shandong, 266000

Connect Investigative Site 2011, Shanghai, Shanghai, China

Status

Recruiting

Address

Connect Investigative Site 2011

Shanghai, Shanghai, 200025

Connect Investigative Site 2007, Shanghai, Shanghai, China

Status

Recruiting

Address

Connect Investigative Site 2007

Shanghai, Shanghai, 200040

Connect Investigative Site 2019, Shanghai, Shanghai, China

Status

Recruiting

Address

Connect Investigative Site 2019

Shanghai, Shanghai, 200065

Connect Investigative Site 2035, Shanghai, Shanghai, China

Status

Recruiting

Address

Connect Investigative Site 2035

Shanghai, Shanghai, 200080

Connect Investigative Site 2038, Shanghai, Shanghai, China

Status

Recruiting

Address

Connect Investigative Site 2038

Shanghai, Shanghai, 200433

Connect Investigative Site 2020, Taiyuan, Shanxi, China

Status

Recruiting

Address

Connect Investigative Site 2020

Taiyuan, Shanxi, 030001

Connect Investigative Site 2013, Chengdu, Sichuan, China

Status

Recruiting

Address

Connect Investigative Site 2013

Chengdu, Sichuan, 610041

Connect Investigative Site 2043, Chongqing, Sichuan, China

Status

Recruiting

Address

Connect Investigative Site 2043

Chongqing, Sichuan, 400037

Connect Investigative Site 2032, Hangzhou, Zhejiang, China

Status

Recruiting

Address

Connect Investigative Site 2032

Hangzhou, Zhejiang, 310009

Connect Investigative Site 2203, Chernivtsi, Ukraine

Status

Not yet recruiting

Address

Connect Investigative Site 2203

Chernivtsi, , 58002

Connect Investigative Site 2211, Dnipro, Ukraine

Status

Not yet recruiting

Address

Connect Investigative Site 2211

Dnipro, , 49005

Connect Investigative Site 2202, Kharkiv, Ukraine

Status

Not yet recruiting

Address

Connect Investigative Site 2202

Kharkiv, , 61037

Connect Investigative Site 2210, Kharkiv, Ukraine

Status

Not yet recruiting

Address

Connect Investigative Site 2210

Kharkiv, , 61058

Connect Investigative Site 2208, Kharkiv, Ukraine

Status

Not yet recruiting

Address

Connect Investigative Site 2208

Kharkiv, , 61124

Connect Investigative Site 2205, Kyiv, Ukraine

Status

Not yet recruiting

Address

Connect Investigative Site 2205

Kyiv, , 1135

Connect Investigative Site 2206, Kyiv, Ukraine

Status

Not yet recruiting

Address

Connect Investigative Site 2206

Kyiv, , 2091

Connect Investigative Site 2213, Vinnytsia, Ukraine

Status

Not yet recruiting

Address

Connect Investigative Site 2213

Vinnytsia, , 21005

Connect Investigative Site 2204, Vinnytsia, Ukraine

Status

Not yet recruiting

Address

Connect Investigative Site 2204

Vinnytsia, , 21018

Connect Investigative Site 2209, Vinnytsia, Ukraine

Status

Not yet recruiting

Address

Connect Investigative Site 2209

Vinnytsia, , 21021

Connect Investigative Site 2214, Zaporizhzhia, Ukraine

Status

Not yet recruiting

Address

Connect Investigative Site 2214

Zaporizhzhia, , 69035

Connect Investigative Site 2212, Úzhgorod, Ukraine

Status

Not yet recruiting

Address

Connect Investigative Site 2212

Úzhgorod, , 88000

Connect Investigative Site 2201, Úzhgorod, Ukraine

Status

Not yet recruiting

Address

Connect Investigative Site 2201

Úzhgorod, , 88009

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation. For a full description of terms please refer to our Terms, Conditions & Privacy.